Anteris Technologies Global Corp. (AVR) AI Stock Analysis

• Market Cap: $167.33M
• Dividend Yield: N/A
• Average Volume (3M): 116.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.89
• Revenue Growth: -2.44%
• EPS Growth: -40.08%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): -2.12
• Shares Outstanding: 36,062,370
• 10 Day Avg. Volume: 110,655
• 30 Day Avg. Volume: 116,741
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: 44.64
• Enterprise Value/Gross Profit: 75.14
• Enterprise Value/Ebitda: -1.74
• 1Y Price Target: $12.83
• Price Target Upside: 176.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 47 Neutral
• Price Target: $3.50 ▼(-24.57% Downside)

Anteris Technologies Global Corp. has a low overall stock score due to significant financial challenges, including declining revenues and persistent losses. The technical analysis indicates a bearish trend, and the valuation is unattractive with a negative P/E ratio. However, the recent ASX waiver for securities issuance is a positive corporate event, providing potential strategic opportunities.

Positive Factors

Clinical Trials

Preparations for the PARADIGM pivotal trial accelerated, with 79 sites qualified and global investigator meetings held.

Product Performance

The accumulating data reinforce the platform’s differentiated performance profile versus commercially available TAVR technologies.

Regulatory Progress

Anteris released its Q4 results, highlighting significant progress toward securing FDA approval for the DurAVR TAVR system.

Negative Factors

Manufacturing Challenges

Key milestones include manufacturing scale-up, which is crucial for advancing the DurAVR toward pivotal trial.

Regulatory Challenges

The company engaged in multiple pre-submission meetings with the FDA to review critical aspects of the pivotal trial.

Anteris Technologies Global Corp. Business Overview & Revenue Model

Company Description

Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.

How the Company Makes Money

Anteris Technologies generates revenue primarily through the sale of its medical devices, particularly its heart valve products. The company employs a direct sales model, targeting hospitals and medical professionals who require advanced cardiovascular solutions. Additionally, Anteris may engage in partnerships with healthcare providers and distributors to expand its market reach. Revenue is also supported by clinical trials and research grants that validate its technologies, as well as potential licensing agreements for its intellectual property. The company’s earnings are influenced by the demand for innovative heart treatments and its ability to establish a strong presence in the competitive medical device market.

Anteris Technologies Global Corp. Financial Statement Overview

Summary

Anteris Technologies Global Corp. faces significant financial challenges, with declining revenues and persistent losses. Despite a strong equity base and low leverage, profitability and cash flow generation remain weak. Improvements in gross profit margin and free cash flow growth are positive signs, but operational inefficiencies and revenue growth need addressing.

Income Statement

Anteris Technologies Global Corp. has experienced declining revenue over the past years, with a significant drop in 2024. The gross profit margin improved to 46.8% in 2024, indicating better cost management, but the company remains unprofitable with a net profit margin of -28.2%. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio is low at 0.022, suggesting minimal leverage, which is a positive aspect. However, the return on equity is negative, indicating that the company is not generating returns for its shareholders. The equity ratio stands at 77.8%, showing a strong equity base relative to total assets.

Cash Flow

Free cash flow has shown some improvement with a growth rate of 19.2% in 2024, but operating cash flow remains negative. The operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is slightly better aligned with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.48M	2.70M	2.73M	3.20M	5.83M
Gross Profit	1.47M	1.27M	876.80K	298.38K	1.91M
EBITDA	-63.75M	-76.86M	-45.54M	-29.14M	-15.50M
Net Income	-84.23M	-76.29M	-46.02M	-30.56M	-17.17M
Balance Sheet
Total Assets	39.88M	80.70M	30.53M	15.99M	21.43M
Cash, Cash Equivalents and Short-Term Investments	28.44M	70.46M	21.03M	9.29M	15.46M
Total Debt	2.81M	1.40M	1.60M	952.79K	4.14M
Total Liabilities	15.85M	18.02M	11.63M	6.95M	10.91M
Stockholders Equity	24.41M	62.76M	19.30M	9.03M	10.52M
Cash Flow
Free Cash Flow	-74.53M	-63.51M	-37.03M	-31.08M	-15.02M
Operating Cash Flow	-73.36M	-61.24M	-34.63M	-29.42M	-14.44M
Investing Cash Flow	-343.63K	-2.28M	-2.58M	-992.57K	-886.07K
Financing Cash Flow	95.35M	112.83M	49.34M	23.27M	27.42M

Anteris Technologies Global Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	74 Outperform	$266.85M	20.27	10.79%	―	17.11%	45.34%
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
AVR	47 Neutral	$167.33M	―	-615.48%	―	-2.44%	-40.08%
LNSR	47 Neutral	$147.28M	―	-350.22%	―	29.34%	-283.53%
NUWE	44 Neutral	$4.31M	―	-440.77%	―	-7.72%	99.54%
SINT	42 Neutral	$12.66M	―	-195.48%	―	-40.47%	96.14%
BMRA	40 Underperform	$8.19M	―	-92.99%	―	-1.88%	23.99%

Anteris Technologies Global Corp. Corporate Events

Anteris Technologies Postpones Special Stockholders Meeting

On September 4, 2025, Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders, originally scheduled for September 4, to September 11, 2025. The delay aims to provide stockholders additional time to vote, facilitating broader participation. The company’s Board of Directors recommends voting in favor of the proposals in the Proxy Statement filed with the SEC on August 18, 2025.

Anteris Technologies Receives ASX Waiver for Securities Issuance

On August 7, 2025, Anteris Technologies Global Corp. announced that it received a waiver from the Australian Securities Exchange (ASX) allowing the company to issue securities without stockholder approval under ASX Listing Rule 7.1. This waiver provides Anteris with greater flexibility in financing and capital raising, aligning its operations more closely with U.S. public companies not subject to similar restrictions. The waiver is contingent on compliance with Nasdaq Listing Rules and U.S. securities laws, and it will remain effective for three years following stockholder approval. The waiver’s impact is expected to enhance Anteris’s ability to pursue strategic financial opportunities, potentially benefiting its stakeholders.

Anteris Technologies Enters New Agreement with Switchback

On July 28, 2025, Anteris Technologies Global Corp. entered into an amended and restated master services agreement with Switchback Medical, LLC. This agreement involves Switchback providing various development and manufacturing services, including engineering and testing, under set terms and conditions. The agreement grants Switchback a limited license to use certain intellectual property of Anteris for manufacturing purposes, while Anteris retains all rights to the results of any testing and developed intellectual property. The agreement is set to expire on March 31, 2028, with automatic renewals unless terminated by either party.